Dave Knapp brings you your weekly dose of everything in the news about incretin mimetic, diabetes and obesity therapies, like Zepbound and Mounjaro, Ozempic and Wegovy, and even investigational treatments like CagriSema and Retatrutide!
All content for On The Pen With Dave Knapp is the property of Bleav, Dave Knapp Founder of On The Pen and is served directly from their servers
with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
Dave Knapp brings you your weekly dose of everything in the news about incretin mimetic, diabetes and obesity therapies, like Zepbound and Mounjaro, Ozempic and Wegovy, and even investigational treatments like CagriSema and Retatrutide!
Retatrutide News That Could Change Everything for GLP-1 Compounds
On The Pen With Dave Knapp
40 minutes 26 seconds
4 weeks ago
Retatrutide News That Could Change Everything for GLP-1 Compounds
This episode of *On The Pen* dives into three major developments shaping obesity care: Fractyl Health’s groundbreaking GLP-1 + GIP gene therapy, Dr. Mehmet Oz’s hints about potential Medicare coverage for GLP-1s, and the federal court ruling on retatrutide that could redefine compounded access. Together, these stories reveal how science, policy, and regulation are colliding to decide the future of obesity treatment.
On The Pen With Dave Knapp
Dave Knapp brings you your weekly dose of everything in the news about incretin mimetic, diabetes and obesity therapies, like Zepbound and Mounjaro, Ozempic and Wegovy, and even investigational treatments like CagriSema and Retatrutide!
